Shopping on Shein and Temu for holiday gifts? You're not the only one
Sen. Mitch McConnell said Thursday he will lead a subcommittee overseeing defense spending as he carves out new roles once he relinquishes his long-running post as Senate Republican leader. The Kentucky Republican revealed he will assume the chairmanship of the Senate Appropriations Subcommittee on Defense. The role dovetails with his constant message that America needs a bulked-up military to deter threats from adversaries such as Russia, Iran and China. The transition comes as McConnell is ending his role as the longest-serving Senate leader in history, just as Republicans prepare to take majority control of the chamber after big gains in this month's election. Republicans elected South Dakota Sen. John Thune , a top deputy to McConnell, as the next Senate majority leader. McConnell, 82, said Thursday he will assume the subcommittee chairmanship at a critical time. “America’s national security interests face the gravest array of threats since the Second World War," the senator said in a statement. “At this critical moment, a new Senate Republican majority has a responsibility to secure the future of U.S. leadership and primacy.” McConnell frequently evokes Ronald Reagan’s mantra of “peace through strength” when discussing foreign policy risks and how the U.S. should respond. McConnell's stance could clash with President-elect Donald Trump’s “America First” doctrine on foreign affairs. McConnell worked with Trump on a tax cuts package and the appointment of conservative judges — including three justices to the nine-member Supreme Court — during Trump's first term as president. Fighting back against isolationism within his own party, McConnell has championed sending weapons and other aid to Ukraine as it fends off Russia’s invasion. McConnell said Thursday he's also set to become chairman of the Senate Rules Committee, which is often a more low-key panel at the center of big issues, both at the Capitol and in the country. The committee oversees the administration of the Senate side of the building, including during inaugurations. But it also puts McConnnell at the center of weighty topics, namely federal elections and voting rights as well as the procedures of the Senate, including the debate around the filibuster. McConnell said the committee will have important work in the coming two years. “Defending the Senate as an institution and protecting the right to political speech in our elections remain among my longest-standing priorities,” he said. There had been considerable speculation about what roles McConnell would take after stepping down as Republican leader. He has two years left in his current Senate term and has not signaled whether he will run for reelection in Kentucky in 2026. McConnell has been a prolific appropriator for the Bluegrass State, a role he’s well positioned to continue.Embiid scores 31 in triumphant NBA return for 76ers
NEW YORK , Dec. 23, 2024 /PRNewswire/ -- AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of November 30, 2024 . AllianceBernstein Global High Income Fund, Inc. Top 10 Fixed-Income Holdings Portfolio % 1) U.S. Treasury Notes 2.25%, 02/15/27 1.05 % 2) CCO Holdings 4.50%, 08/15/30 - 06/01/33 0.80 % 3) CCO Holdings 4.75%, 02/01/32 0.64 % 4) Dominican Republic Intl Bond 8.625%, 04/20/27 0.60 % 5) Royal Caribbean Cruises 5.50%, 08/31/26 - 04/01/28 0.53 % 6) AMMC CLO 25 Ltd. 11.406%, 04/15/35 0.51 % 7) Altice France SA 5.125%, 01/15/29 - 07/15/29 0.46 % 8) DaVita, Inc. 4.625%, 06/01/30 0.46 % 9) Bausch Health Cos., Inc. 4.875%, 06/01/28 0.43 % 10) EchoStar Corp. 10.75%, 11/30/29 0.42 % Investment Type Portfolio % Corporates - Non-Investment Grade Industrial Energy 7.41 % Consumer Non-Cyclical 7.04 % Communications - Media 6.97 % Capital Goods 4.53 % Basic 4.27 % Consumer Cyclical - Other 3.78 % Communications - Telecommunications 3.75 % Consumer Cyclical - Retailers 3.27 % Services 2.66 % Consumer Cyclical - Automotive 2.36 % Technology 2.02 % Consumer Cyclical - Entertainment 1.74 % Transportation - Services 1.30 % Transportation - Airlines 0.70 % Consumer Cyclical - Restaurants 0.52 % Other Industrial 0.41 % Transportation - Railroads 0.04 % SUBTOTAL 52.77 % Credit Default Swaps 14.44 % Financial Institutions Finance 2.14 % Brokerage 1.16 % REITs 1.11 % Insurance 0.87 % Other Finance 0.55 % Banking 0.50 % SUBTOTAL 6.33 % Utility Electric 1.35 % Natural Gas 0.06 % SUBTOTAL 1.41 % SUBTOTAL 74.95 % Corporates - Investment Grade Industrial Communications - Media 1.37 % Energy 1.22 % Consumer Cyclical - Automotive 0.87 % Consumer Cyclical - Other 0.73 % Basic 0.66 % Consumer Non-Cyclical 0.47 % Capital Goods 0.43 % Transportation - Airlines 0.38 % Consumer Cyclical - Entertainment 0.30 % Transportation - Services 0.21 % Consumer Cyclical - Retailers 0.20 % Other Industrial 0.05 % Technology 0.03 % Transportation - Railroads 0.03 % Services 0.02 % SUBTOTAL 6.97 % Financial Institutions Banking 4.30 % Insurance 0.82 % Finance 0.64 % REITs 0.37 % Brokerage 0.13 % SUBTOTAL 6.26 % Utility Electric 1.41 % Other Utility 0.05 % SUBTOTAL 1.46 % SUBTOTAL 14.69 % Emerging Markets - Corporate Bonds Industrial Basic 1.95 % Energy 1.13 % Consumer Cyclical - Other 0.96 % Consumer Non-Cyclical 0.79 % Capital Goods 0.26 % Communications - Telecommunications 0.16 % Consumer Cyclical - Retailers 0.14 % Communications - Media 0.09 % Transportation - Services 0.07 % Other Industrial 0.03 % Consumer Cyclical - Automotive 0.02 % SUBTOTAL 5.60 % Utility Electric 0.44 % Other Utility 0.07 % SUBTOTAL 0.51 % Financial Institutions Banking 0.12 % SUBTOTAL 0.12 % SUBTOTAL 6.23 % Bank Loans Industrial Consumer Non-Cyclical 0.98 % Technology 0.98 % Communications - Media 0.67 % Communications - Telecommunications 0.50 % Transportation - Airlines 0.23 % Capital Goods 0.20 % Other Industrial 0.16 % Energy 0.15 % Consumer Cyclical - Retailers 0.05 % Consumer Cyclical - Restaurants 0.02 % SUBTOTAL 3.94 % Financial Institutions Insurance 0.38 % Finance 0.02 % SUBTOTAL 0.40 % SUBTOTAL 4.34 % Interest Rate Futures 3.22 % Collateralized Loan Obligations CLO - Floating Rate 2.83 % SUBTOTAL 2.83 % Collateralized Mortgage Obligations Risk Share Floating Rate 1.55 % Non-Agency Fixed Rate 0.31 % Non-Agency Floating Rate 0.28 % Agency Fixed Rate 0.21 % SUBTOTAL 2.35 % Emerging Markets - Sovereigns 2.33 % U.S. Govt & Agency Securities 1.62 % Quasi-Sovereigns Quasi-Sovereign Bonds 1.20 % SUBTOTAL 1.20 % Local Governments - US Municipal Bonds 0.40 % Commercial Mortgage-Backed Securities Non-Agency Fixed Rate CMBS 0.35 % SUBTOTAL 0.35 % Asset-Backed Securities Other ABS - Floating Rate 0.22 % Autos - Fixed Rate 0.08 % SUBTOTAL 0.30 % Emerging Markets - Treasuries 0.24 % Inflation-Linked Securities 0.22 % Forward Currency Exchange Contracts Currency Instruments 0.13 % SUBTOTAL 0.13 % Common Stocks 0.12 % Preferred Stocks Industrials 0.09 % SUBTOTAL 0.09 % Reverse Repurchase Agreements -0.55 % EM Government Agencies -0.81 % Cash & Cash Equivalents Cash 1.20 % Funds and Investment Trusts 0.69 % SUBTOTAL 1.89 % Derivative Offsets Futures Offsets -3.20 % Swap Offsets -12.94 % SUBTOTAL -16.14 % TOTAL 100.00 % Country Breakdown Portfolio % United States 68.28 % United Kingdom 3.37 % Canada 2.47 % France 2.28 % Germany 1.54 % Brazil 1.50 % Colombia 1.43 % Mexico 1.32 % Italy 1.23 % Spain 1.22 % Luxembourg 1.08 % India 1.04 % South Africa 0.90 % Dominican Republic 0.85 % Israel 0.82 % Chile 0.77 % Australia 0.63 % China 0.61 % Peru 0.58 % Nigeria 0.57 % Hong Kong 0.52 % Macau 0.51 % Netherlands 0.50 % Puerto Rico 0.44 % Turkey 0.38 % Kazakhstan 0.36 % Angola 0.31 % Finland 0.31 % Switzerland 0.31 % Ireland 0.30 % Indonesia 0.25 % Jersey (Channel Islands) 0.25 % Egypt 0.24 % Norway 0.21 % Panama 0.21 % Slovenia 0.20 % Romania 0.19 % Zambia 0.17 % El Salvador 0.16 % Guatemala 0.14 % Azerbaijan 0.11 % Ukraine 0.10 % Ecuador 0.09 % Malaysia 0.08 % Cayman Islands 0.07 % Japan 0.07 % Argentina 0.05 % Jamaica 0.05 % Austria 0.04 % Czech Republic 0.04 % Kuwait 0.04 % Morocco 0.04 % Serbia 0.03 % Uzbekistan 0.03 % Trinidad and Tobago 0.02 % Cash & Cash Equivalents 0.69 % Total Investments 100.00 % Net Currency Exposure Breakdown Portfolio % US Dollar 100.27 % Canadian Dollar 0.18 % Pound Sterling 0.10 % Dominican Peso 0.07 % Norwegian Krone 0.02 % Brazilian Real 0.01 % Indonesian Rupiah 0.01 % Swedish Krona 0.01 % South African Rand 0.01 % South Korean Won -0.01 % Colombian Peso -0.09 % Euro -0.58 % Total Net Assets 100.00 % Credit Rating Portfolio % AAA 1.36 % AA 0.20 % A 1.24 % BBB 15.93 % BB 44.82 % B 23.26 % CCC 8.14 % CC 0.11 % C 0.05 % Not Rated 2.89 % Short Term Investments 0.69 % Reverse Repurchase Agreements -0.54 % N/A 1.85 % Total 100.00 % Bonds by Maturity Portfolio % Less than 1 Year 7.30 % 1 To 5 Years 66.36 % 5 To 10 Years 21.85 % 10 To 20 Years 2.50 % 20 To 30 Years 1.64 % More than 30 Years 0.23 % Other 0.12 % Total Net Assets 100.00 % Portfolio Statistics: Average Coupon: 7.45 % Average Bond Price: 96.67 Percentage of Leverage(based on gross assets): Bank Borrowing: 0.00 % Investment Operations:* 14.91 % Preferred Stock: 0.00 % Tender Option Bonds: 0.00 % VMTP Shares: 0.00 % VRDP Shares: 0.00 % Total Fund Leverage: 14.91 % Average Maturity: 4.57 Years Effective Duration: 3.06 Years Total Net Assets: $987.60 Million Net Asset Value: $11.45 Total Number of Holdings: 1,240 Portfolio Turnover: 45.00 % * Investment Operations may include the use of certain portfolio management techniques such as credit default swaps, dollar rolls, negative cash, reverse repurchase agreements and when-issued securities. The foregoing portfolio characteristics are as of the date indicated and can be expected to change. The Fund is a closed-end U.S.-registered management investment company advised by AllianceBernstein L. P. View original content: https://www.prnewswire.com/news-releases/alliancebernstein-global-high-income-fund-inc-releases-monthly-portfolio-update-302338564.html SOURCE AllianceBernstein Global High Income Fund, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Philadelphia's Joel Embiid scored 31 points and pulled down 12 rebounds in his return after missing seven games to spark the 76ers on Sunday in a 108-100 NBA victory at Chicago. Embiid had been sidelined by a left knee injury and personal reasons since a November 20 loss to Memphis, the Sixers going 4-3 in his absence.
Jacqueline N. Hernandez Kicks Off Book Signing Tour For 'Entrepreneurial Empire - Master The Leap: From Hustling Dreams To Empire Realities.'The forum will explore Legal and Regulatory Frameworks to create balanced, growth-oriented policies that strengthen Internet governance. New Delhi: The India Internet Governance Forum (IIGF) 2024 will be held on December 9-10 at the Bharat Mandapam Convention Centre, Pragati Maidan in the national capital, according to an official statement issued on Sunday. Supported by the Ministry of Electronics and Information Technology (MeitY) and the National Internet Exchange of India (NIXI), this initiative by India's multi-stakeholder community aims to explore critical aspects of Internet governance, foster meaningful dialogue, and highlight India's leadership in the global digital landscape. The event will be inaugurated by the Union Minister of State for Electronics & Information Technology and Commerce and Industry Jitin Prasada, in the presence of S. Krishnan, Secretary, MeitY. After the successful hybrid editions of IIGF in 2021, 2022, and 2023, the fourth edition will be conducted under the theme "Innovating Internet Governance for India". The forum will focus on bridging the digital divide, enhancing trust and safety in the online environment, and leveraging advanced technologies for nation-building while emphasizing the need for a secure, inclusive, and ethically governed Internet, the official statement read. IIGF 2024 will address critical themes to advance a secure, inclusive, and sustainable digital ecosystem. The discussions will focus on Empowering Connections, emphasizing enhanced access, inclusion, and digital rights to bridge the digital divide. The forum will explore Legal and Regulatory Frameworks to create balanced, growth-oriented policies that strengthen Internet governance. Another key focus is Responsible AI, promoting the ethical and effective use of artificial intelligence for societal benefit. Additionally, Building a Greener and Sustainable Internet will highlight energy-efficient practices and environmental sustainability in the digital realm, while Trust and Safety will address measures to enhance cybersecurity and boost user confidence in the online environment. These comprehensive discussions will unite stakeholders from various sectors to tackle pressing challenges and harness opportunities in Internet governance, the statement added. The India Internet Governance Forum (IIGF) is the Indian chapter of the United Nations Internet Governance Forum (UN IGF), a global multi-stakeholder platform that fosters dialogue on public policy issues related to the Internet. Established in 2021, IIGF promotes collaborative discussions among representatives from government, civil society, industries, technical communities, think tanks, and industry associations. Supported by a 14-member multi-stakeholder committee, IIGF aims to maximise the opportunities of the Internet while addressing associated challenges and risks. Known for its inclusive and collaborative approach, IGF plays a vital role in shaping policies for an open, secure, and accessible Internet, addressing issues such as cybersecurity, digital inclusion, data privacy, and emerging technologies. Stay informed on all the latest news , real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.
PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023 . The injunction, which the Court said it will enter in January 2025 , is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023 . Such customers can continue to purchase GeoMx reagents for use with existing GeoMx instruments for purposes of continuing their ongoing research. The Court found that making such an exception for ongoing research strikes a "workable balance between protecting the patentee's rights and protecting the public from the injunction's adverse effects." In addition, the Court affirmed the $31 million damages awarded by the November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered. "Today's decision helps to safeguard our decade-long investment in innovation and ensures we can continue to develop groundbreaking technologies that help our customers revolutionize science," said Eric Whitaker , Chief Legal Officer at 10x Genomics. "10x exists to fuel scientific progress – not stifle it – and that is why we've done our utmost to ensure this injunction was structured to protect both our intellectual property and existing GeoMx customers' ongoing research." The Court recognized the harm NanoString's infringing conduct caused 10x when it wrote in its ruling, "Having been careful not to license its technology, 10x suffers when it proclaims itself as an innovator in spatial genomics but a competitor is using the same innovative, patented technology." Today's Court decision follows a November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys. During the trial, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee , and NanoString CEO Brad Gray and NanoString CSO Joe Beechem. After hearing all of the evidence, the jury determined that all seven patents had been infringed by NanoString, that each patent was valid, that NanoString willfully infringed those patents and that monetary damages were owed to 10x for the infringement of all seven patents. In affirming the jury's finding that NanoString willfully infringed, the Court relied on the evidence showing that NanoString knew or was willfully blind that its acts would cause infringement of 10x's rights. The asserted patents in Case No. 21-cv-653-MFK include (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter) . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and remedies as well as possible outcomes of litigation. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable or there may be changes in our litigation strategy. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-awards-10x-genomics-permanent-injunction-in-patent-infringement-lawsuit-against-bruker-corporations-geomx-products-302338627.html SOURCE 10x Genomics, Inc.You can still score a PlayStation 5 for as low as $374 for Black Friday
NoneScottie Scheffler in a landslide to win PGA Tour player of the year for third straight timeMSNBC Personalities Panic Over New Attorney General Nominee Pam Bondi: 'Worse Than ... Matt Gaetz'
Atlético 5-0 Valladolid (Nov 30, 2024) Game Analysis - ESPNStock market today: Wall Street slips to a rare back-to-back loss
Man throws liquid on Kejriwal, held; BJP behind it: AAP; Oppn. party junks claimPhiladelphia's Joel Embiid scored 31 points and pulled down 12 rebounds in his return after missing seven games to spark the 76ers on Sunday in a 108-100 NBA victory at Chicago. Embiid had been sidelined by a left knee injury and personal reasons since a November 20 loss to Memphis, the Sixers going 4-3 in his absence. The 30-year-old Cameroonian-born big man, who wore a left knee brace, also added four assists and two blocked shots in 33 minutes in only his fifth game of the season. "He caught fire there," 76ers coach Nick Nurse said of Embiid. "Certainly he gave us a lot of confidence." Philadelphia guard Tyrese Maxey contributed his first career NBA triple-double with 25 points and career highs of 14 assists and 11 rebounds. "It was good," Maxey said. "The offense flowed really well. Pick and roll was really good. I was able to get everybody involved, get Joel going and get myself going too." "He turned on the jets and got to the rim at some pretty opportune times," Nurse said of Maxey. Embiid was a welcome court presence for the 76ers. "He creates so much space for us on the floor, gets the attention," said Maxey. "I didn't see one pick and roll double team for the first time in a long time." Zach LaVine led the Bulls with 30 points. At New York, Milwaukee's Giannis Antetokounmpo scored 34 points and grabbed 11 rebounds to lead the Bucks over the Brooklyn Nets 118-113. Damian Lillard added 15 points and 11 assists while reserve Bobby Portis contributed 23 points and Gary Trent Jr. scored 20 off the Milwaukee bench. Germany's Dennis Schroder led the Nets with 34 points. js/mlmPLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023 . The injunction, which the Court said it will enter in January 2025 , is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023 . Such customers can continue to purchase GeoMx reagents for use with existing GeoMx instruments for purposes of continuing their ongoing research. The Court found that making such an exception for ongoing research strikes a "workable balance between protecting the patentee's rights and protecting the public from the injunction's adverse effects." In addition, the Court affirmed the $31 million damages awarded by the November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered. "Today's decision helps to safeguard our decade-long investment in innovation and ensures we can continue to develop groundbreaking technologies that help our customers revolutionize science," said Eric Whitaker , Chief Legal Officer at 10x Genomics. "10x exists to fuel scientific progress – not stifle it – and that is why we've done our utmost to ensure this injunction was structured to protect both our intellectual property and existing GeoMx customers' ongoing research." The Court recognized the harm NanoString's infringing conduct caused 10x when it wrote in its ruling, "Having been careful not to license its technology, 10x suffers when it proclaims itself as an innovator in spatial genomics but a competitor is using the same innovative, patented technology." Today's Court decision follows a November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys. During the trial, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee , and NanoString CEO Brad Gray and NanoString CSO Joe Beechem. After hearing all of the evidence, the jury determined that all seven patents had been infringed by NanoString, that each patent was valid, that NanoString willfully infringed those patents and that monetary damages were owed to 10x for the infringement of all seven patents. In affirming the jury's finding that NanoString willfully infringed, the Court relied on the evidence showing that NanoString knew or was willfully blind that its acts would cause infringement of 10x's rights. The asserted patents in Case No. 21-cv-653-MFK include (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter) . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and remedies as well as possible outcomes of litigation. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable or there may be changes in our litigation strategy. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-awards-10x-genomics-permanent-injunction-in-patent-infringement-lawsuit-against-bruker-corporations-geomx-products-302338627.html SOURCE 10x Genomics, Inc. Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.
Defence Minister Israel Katz on Monday acknowledged that Israel had killed former Hamas chief Ismail Haniyeh in Tehran earlier this year, as he warned the military would “decapitate” the leadership of Yemen’s Houthi rebels. “We will strike hard at the Houthis ... and decapitate their leadership – just as we did with Haniyeh, [Yahya] Sinwar, and [Hassan] Nasrallah in Tehran, Gaza, and Lebanon, we will do so in Hodeida and Sanaa,” Katz said. “Anyone who raises a hand against Israel will have his hand cut off, and the long arm of the IDF [Israeli Defence Forces] will strike him and hold him accountable,” Katz said, according to a statement issued by the ministry. Until now Israel had never admitted to killing Haniyeh, but Iran and Hamas had blamed it for the Hamas political leader’s death. Haniyeh, who was seen as leading Hamas’s negotiation efforts for a ceasefire in Gaza, was killed in a guest house in Tehran on July 31, reportedly by an explosive device that had been placed by Israeli operatives weeks before.
Israel for first time claims responsibility for Hamas leader’s assassinationStock market today: US stocks rise as Nvidia, Broadcom, lead tech sector higherTech Stocks Drive Wall Street Gains Amid Holiday Trading